Efficacy and safety during long-term treatment of primary monosymptomatic nocturnal enuresis with desmopressin. Swedish Enuresis Trial Group.

Versione stampabileVersione stampabileVersione PDFVersione PDF
TitleEfficacy and safety during long-term treatment of primary monosymptomatic nocturnal enuresis with desmopressin. Swedish Enuresis Trial Group.
Publication TypeJournal Article
Year of Publication1999
AuthorsTullus, K, Bergström, R, Fosdal, I, Winnergård, I, Hjälmås, K
JournalActa Paediatr
Volume88
Issue11
Pagination1274-8
Date Published1999 Nov
ISSN0803-5253
KeywordsAdministration, Intranasal, Child, Confidence Intervals, Deamino Arginine Vasopressin, Dose-Response Relationship, Drug, Drug Administration Schedule, Enuresis, Female, Follow-Up Studies, Humans, Long-Term Care, Male, Patient Compliance, Renal Agents, Sweden
Abstract

The Swedish Enuresis Trial (SWEET) was conducted to evaluate the long-term safety and efficacy of intranasal desmopressin treatment in children with primary, monosymptomatic nocturnal enuresis (PMNE). The study had an open, multicentre design and comprised a 4-wk observation period, a 6-wk dose titration period (with 20-40 microg desmopressin) and a 1-y, long-term treatment period. A treatment-free week was introduced every 3 mo to identify dry patients. In total, 399 children aged 6-12 y with PMNE were recruited. Of these, 245 patients (61%) experienced > or = 50% reduction in the number of wet nights during the last 4 wk of dose titration compared with the observation period. These responders entered the long-term phase of the trial. The mean number of wet nights per week decreased from a median of 5.3 (range 1.3-7.0) during the observation period to a median of 0.8 (range 0.0-5.0) during the last 3-mo period. Seventy-seven children became dry, 63 (83%) within 6 mo of treatment initiation. The percentage of children who became dry was similar in all age groups. Significantly fewer children in the lowest age group were defined as responders (52%; 95% CI 45, 59) among the 6-7-y-olds compared to 65% (56, 74) and 81% (72, 90) in the two older age groups. Desmopressin was well tolerated. No serious drug-related adverse events were recorded and no clinical symptoms of hyponatraemia were reported. The SWEET trial has demonstrated that desmopressin is both safe and effective for the long-term treatment of PMNE, with a significant therapeutic effect also in children of 6-7 y of age.

Alternate JournalActa Paediatr.
Citation Key128
PubMed ID10591433

Top rated content

Admin
Inserito: 4 years ago
Valore:
100
Admin
Inserito: 5 years ago
Valore:
80
TBarina
Inserito: 5 years ago
Valore:
80
Antonio D'Alessio
Inserito: 5 years ago
Valore:
80
Rita Caruso
Inserito: 5 years ago
Valore:
70
Admin
Inserito: 5 years ago
Valore:
70
Admin
Inserito: 5 years ago
Valore:
66.6667
Admin
Inserito: 5 years ago
Valore:
60

Argomenti del forum in attesa di risposte

No unanswered topics.

Recent blog posts

Feedback